Table 1.
Baseline characteristics of study population.
| Controls | PE | GH | chrHTN | CTD | Proteinuria | |
|---|---|---|---|---|---|---|
| Total (n) | 76 | 62 | 12 | 15 | 16 | 13 |
| Age (y) | 29 ± 3 | 31 ± 5 | 33 ± 5 | 31 ± 5 | 31 ± 5 | 33 ± 4 |
| Multipara (%) | 18.4 | 28.6 | 16.6 | 13.3 | 0 | 16.7 |
| Gestational week of test | 30 ± 5 | 31 ± 4 | 33 ± 3 | 32 ± 4 | 32 ± 4 | 30 ± 4 |
| Gestational week of delivery | 39 ± 2 | 32 ± 4a | 38 ± 2 | 39 ± 1 | 37 ± 3 | 39 ± 1 |
| Birthweight (g) | 3198 ± 388 | 1624 ± 703a | 3130 ± 584 | 3167 ± 399 | 2639 ± 616 | 3080 ± 325 |
| sFlt-1/PlGF ratio | 4.1 ± 0.5 | 257.7 ± 44.7a | 38.6 ± 17.4 | 8.9 ± 2.4 | 19.6 ± 6.9 | 10.5 ± 3.5 |
aWomen with PE had a lower mean birthweight of the neonate, a shorter mean gestational week of delivery, and a higher sFlt-1/PlGF ratio than healthy controls or women with GH, chrHTN, CTD, or proteinuria. The difference was significant, P < 0.001.